Prelude Therapeutics (PRLD) Short-term Investments (2021 - 2026)

Prelude Therapeutics has disclosed Short-term Investments across 6 years of filings, most recently posting $59.8 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $59.8 million, up 1.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.8 million (up 1.69% YoY), and the FY2025 annual result was $68.0 million, down 43.9% from the prior year.
• Short-term Investments came in at $59.8 million for Q1 2026 at Prelude Therapeutics, down from $68.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $228.5 million in Q2 2023 to a low of $7.4 million in Q3 2025.
• The 5-year median for Short-term Investments is $154.1 million (2023), against an average of $140.7 million.
• Across the five-year window, Short-term Investments grew 24.76% in 2023 and tumbled 94.79% in 2025, its largest moves.
• Prelude Therapeutics' Short-term Investments stood at $171.1 million in 2022, then increased by 21.34% to $207.6 million in 2023, then slumped by 41.66% to $121.1 million in 2024, then plunged by 43.9% to $68.0 million in 2025, then decreased by 12.01% to $59.8 million in 2026.
• The last three Short-term Investments figures came in at $59.8 million (Q1 2026), $68.0 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.